<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">FSU Council on Research and Creativity<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/cofrs/">Committee on Faculty Research Support (COFRS) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:#7030A0">Pre-review deadline: November 30, 2020, 4:59 p.m.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 10, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: November 30.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/eieg/">Equipment & Infrastructure Enhancement (EIEG) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:#7030A0">Pre-review deadlines: September 21, 2020, 4:59 p.m. and March 1, 2021, 4:59 p.m.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 1, 2020 and March 11, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for October 1 due date: September 21.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/fyap/">First Year Assistant Professor (FYAP) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">FYAP Workshop: September 11, 2020 (mandatory for submitters).<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:#7030A0">Pre-review deadline: October 12, 2020, 4:59 p.m.
<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 22, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 12.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/mds/">Multidisciplinary Support (MDS) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:#7030A0">Pre-review deadline: November 9, 2020, 4:59 p.m.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 19, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: November 9.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/pg/">Planning Grant (PG) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:#7030A0">Pre-review deadlines: September 21, 2020, 4:59 p.m. and March 1, 2021, 4:59 p.m.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 1, 2020 and March 11, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for October 1 due date: September 21.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/sgp/">Small Grants Program (SGP)</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:#7030A0">Pre-review deadlines: September 28, 2020, 4:59 p.m. and March 8, 2021, 4:59 p.m.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 8, 2020 and March 18, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for October 8 due date: September 28.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://wtgrantfoundation.org/library/uploads/2020/04/2020-Guidelines-Institutional-Challenge-Grant.pdf__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzx_gCE_ww$" target="_blank">William T. Grant Foundation: Institutional Challenge Grant</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Institutional Challenge Grant encourages university-based research institutes, schools, and centers to build sustained research-practice partnerships with public agencies or nonprofit
organizations in order to reduce inequality in youth outcomes. To do so, research institutions will need to shift their policies and practices to value collaborative research. They will also need to build the capacity of researchers to produce relevant work
and the capacity of agency and nonprofit partners to use research. Applications are welcome from partnerships in youth-serving areas such as education, justice, child welfare, mental health, immigration, and workforce development. We especially encourage proposals
from teams with African American, Latino, Native American, and Asian American members in leadership roles. The partnership leadership team should include the principal investigator from the research institution and the lead from the public agency or nonprofit
organization.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Up to $650,000 over three years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 10, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: August 27.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-07/GMG_2020-Oncology_ACSAddressingRacialDisparitiesCancerCare.pdf?xel46Y6YRMCCKsTBWf.6xk3ZM6Rpb90F__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxzcsU7Yo$">American Cancer Society
/ Pfizer: Addressing Racial Disparities in Cancer Care</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through the program, grants will be awarded in support of quality improvement projects with the potential to reduce systemic barriers and address disparities in the delivery of cancer
care impacting outcomes for black men and women facing cancer. Projects with the greatest likelihood to directly impact patient care for black patients across multiple cancer types and those that can be scaled or replicated will be given priority. The intent
of the collaboration is to support proposals that address systemic disparities along the continuum of cancer care. Example project proposal topics include screening; diagnosis; treatment selection; treatment outcomes; clinical trials participation; access
to care (e.g., social support, navigation, geographic barriers); socioeconomic barriers; age-related barriers (e.g., under-treatment of older people); management of co-morbidities; and delays in diagnosis, treatment, and/or healthcare delivery. The RFP seeks
to support quality improvement initiatives, not clinical or health services research projects. Grants of up to $400,000 (inclusive of both direct and indirect costs) over two years will be awarded. The total available budget related to this RFP is approximately
$2 million.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 10, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: August 27.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://phsharing.org/small-grant-opportunities/__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxhkPse_4$" target="_blank">Center for Sharing Public Health Services: Small Grants Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Center for Sharing Public Health Services (the “Center”) is offering small grants to support work on cross-jurisdictional sharing (CJS) arrangements designed to advance health equity
by addressing social determinants of health (e.g., affordable housing, jobs with fair pay, quality education, affordable healthy food and public safety), the public health response to COVID-19, structural racism or other related issues.
<b>Up to 5 awards will be made for an amount of up to $10,000 for a project period of up to eight months</b>. Shorter projects will be considered.
<b>All projects must be concluded by June 11, 2021.</b> In addition to funding, Center staff will provide technical assistance tailored to each grantee’s needs. Grantees are expected to share the progress of their efforts during the project period, share results
and lessons learned at the end of the project period and share longer-term activities and results 12 months after the project period ends.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Project Classifications:
</span></b><span style="font-size:12.0pt;font-family:Palatino">(1) Specific CJS arrangement or (2) Use of CJS as a systems change tool.<b><o:p></o:p></b></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 11, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: August 31.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.scleroderma.org/site/SPageServer/?pagename=prof_research_types*.XU2BXtNKjfY__;Iw!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxkyrahOA$" target="_blank">Scleroderma Foundation: New and Established Investigator Grant Programs</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Scleroderma Foundation seeks applications from promising new and established investigators both inside and outside the field of scleroderma research who wish to propose pilot studies
to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to the disease. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal
sources.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">New Investigator:</span></b><span style="font-size:12.0pt;font-family:Palatino"> 3 year projects; $50,000 per year; 8% IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Established Investigator:</span></b><span style="font-size:12.0pt;font-family:Palatino"> 2 year projects; $75,000 per year; 8% IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 15, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: September 1.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-022.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxjJ84yCI$">Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this FOA is to solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic
value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 15, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: September 1.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-014.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxOMmm_oQ$">Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2
in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed
project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 15, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: September 1.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-018.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzx1kLOpW8$">Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches
for SARS-CoV-2 (U18 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 18, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: September 8.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxFZeeRdc$">Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01
Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and
institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not
interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance
modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate
ideas and approaches from multiple disciplines, as appropriate.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 30, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: September 17.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-023.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzxbekrreo$">Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory
Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify
and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be
infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 30, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: September 17.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-270.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzxw2RFZNY$" target="_blank">NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated
clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about
the research mission and high-priority research areas of the NIAID (<a href="https://urldefense.com/v3/__https://www.niaid.nih.gov/research/role__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxGcq-gjY$">https://www.niaid.nih.gov/research/role</a>).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 14, 2020; January 12, 2021; May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; and May 12, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for September 14 due date: September 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Cellular and Molecular Biology of Complex Brain Disorders (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-264.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxtYVozyI$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-263.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxWpvvXao$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements (FOAs) encourage research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular,
transcellular, and circuit substrates of neural function. For the purposes of these FOAs, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain
disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize
<i>in vivo, in situ</i>, or <i>in vitro</i> experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular,
transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular
and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated
with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic
target identification. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 5 R01 standard date: September 22. Med-RA deadline to receive draft documents for October 16 R21 standard date: October 5.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-007.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxZP8Sw0o$" target="_blank">Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Accumulation of abnormal proteins such as alpha-synuclein or tau in the brains of patients with dementia tends to occur in specific brain structures (cells/circuits/regions), resulting
in the unique clinical presentations that are characteristic of the different types of dementia. This funding opportunity announcement invites applications that seek to identify mechanisms responsible for this selective regional vulnerability to abnormal protein
deposition in the brains of patients with Lewy Body Dementia or Frontotemporal Dementia.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 27, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 14. </span>
<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-006.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxJQKysz4$" target="_blank">Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not
Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or
Lewy Body Dementia. Applications that move beyond a focus on one mechanism of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 27, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 14. </span>
<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-259.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxltV8oc8$" target="_blank">NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIAID New Innovator Award supports a postdoctoral or newly independent
<a href="https://urldefense.com/v3/__https://grants.nih.gov/policy/early-investigators/index.htm__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxTGFsKRE$">Early Stage Investigator</a> of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms,
or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals
with diverse backgrounds and in any topic relevant to the <a href="https://urldefense.com/v3/__https://www.niaid.nih.gov/research/role__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxGcq-gjY$">
mission of NIAID</a> are welcome.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 2, 2020; October 14, 2021; and October 14, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for November 2 due date: October 20.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-284.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxNEEaUXo$" target="_blank">Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects
should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are
expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets
<i>in vivo</i> and/or characterization of detection and diagnostic devices and sensors
<i>in vitro</i>. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 4, 2020; May 6, 2021; November 4, 2021; May 5, 2021; November 3, 3022; and May 4, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for November 4 due date: October 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-043.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxWINACkg$" target="_blank">Systematic Characterization of Genomic Variation on Genome Function and Phenotype (UM1 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA seeks applications to experimentally correlate genomic variants with their effects on genomic function. This will be accomplished by performing systematic perturbation; collecting
data on the effects of non-coding and protein-coding genomic variation on molecular, cellular, and organismal phenotypes; generating a catalog of these variant effects; and assisting in a group predictive modeling effort using the data. This will also be accomplished
by enabling others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function (IGVF)
Consortium. As members of this Consortium, functional characterization centers will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease through the
coordination of data collection strategies and analyses.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 4, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-044.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzxp1PawRk$" target="_blank">Defining Genomic Influence on Gene Network Regulation (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA seeks applications for research projects to explore the effects of genomic variation on phenotypes at the network level. Research projects supported through this FOA will measure
changes in the activity of genes and regulatory elements during biological transitions and use generalizable analytical approaches to understand network-level relationships among genomic variation, functional elements, genes, and phenotypes related to human
health and disease. Funded projects will also enable others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Projects funded through this initiative will become part of the Impact
of Genomic Variation on Function Consortium. As members of this Consortium, network projects will be expected to work with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 4, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 22.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-045.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzx42CdggM$" target="_blank">Single-cell Profiling of Regulatory Element and Gene Activity in Relationship to Genome Function
(UM1 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to establish Mapping Centers that will generate single-cell, multi-omic maps of genes and regulatory elements in the human and mouse
genomes. This will be accomplished through use of high-throughput state-of-the-art methods to profile biochemical features characteristic of genomic elements while preserving information about biological and/or spatial context. As a group, Mapping Centers
will be expected to pursue studies that will provide a range of data types that will best enable the association of gene and regulatory element activity with specific cell fates and states. Mapping Centers will also enable others to perform related research
by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this consortium, Mapping Centers
will be expected to work closely with one another and other consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 4, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-047.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzx_KLIhKQ$" target="_blank">Developing Predictive Models of the Impact of Genomic Variation on Function (U01 Clinical Trial
Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA seeks applications for Predictive Modeling Projects that will develop and apply innovative computational models to predict the impact of genomic variation on genome function and/or
phenotype and generate a catalog of variant effects. Projects will also enable others to perform related research by sharing approaches and standards and by identifying methodological strengths and weaknesses. Projects funded through this initiative will become
part of the Impact of Genomic Variation on Function Consortium. As members of this Consortium, predictive modeling projects will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation
impacts human health and disease.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 4, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 22.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/rcrp__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxvYPCBUw$" target="_blank">Rare Cancers Research Program</a><br>
Concept Award<b><br>
Pre-application (letter of intent): November 12, 2020. Application: November 30, 2020.<br>
</b>Idea Development Award<b><br>
Pre-application (letter of intent): November 12, 2020. Application: November 30, 2020.<br>
</b>Resource and Community Development Award<b><br>
Pre-application (letter of intent): November 12, 2020. Application: November 30, 2020.<o:p></o:p></b></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application due date: November 16.</span></b><b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-024.html__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxcopG1WE$" target="_blank">NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIDDK Catalyst Award is designed to complement NIDDK’s traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational
studies in topic areas of interest to NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK’s Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges, and have the potential to
produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are
distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 6, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: December 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Forecasts<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=328672__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxiQbkwLY$">Addressing Racial and Ethnic Disparities to Improve Health Outcomes</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The HHS Office of Minority Health is offering funding to support State and local collaborative teams in implementing a methodological framework and strategies for assessing and addressing
structural racism in health policies, developed through a complementary policy academy initiative. In particular, awardees will: (1) Obtain governmental and public buy-in for engaging in this policy collaborative endeavor; (2) Create a multi-sector team (e.g.,
comprised of leadership from the governor's/mayor's office and health, behavioral health, child welfare, justice, education, commerce, community service and other agencies, and from community organizations); (3) Conduct a review of existing policies to identify
the areas primed for a structural racism assessment; (4) Develop or revise a policy (or policies) to address structural racism and improve health outcomes; (5) Implement the new/revised policy and evaluate its impact on health outcomes for racial and ethnic
minorities within their jurisdiction; and (6) Create and implement strategies to communicate, sustain and spread policies resulting in improved health outcomes for racial and ethnic minorities. BACKGROUND: Racial and ethnic minority populations experience
a number of disparities which contribute to poor health outcomes. Structural racism, evidenced in residential segregation, inequitable allocation and quality of services and resources such as health care and education, disproportionate contact with the justice
system, and lack of access to employment opportunities, plays a persistent and large role in historical disadvantage and supports the persistence of racial and ethnic health disparities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date: December 31, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated application deadline: March 31, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=328505__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxnNe7ErI$">Family-Centered Approaches to Improving Type 2 Diabetes Control and Prevention</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The HHS Office of Minority Health will offer funding for an initiative to test and disseminate models/protocols that use a theoretically-based family-centered approach to promote the management
and prevention of Type 2 diabetes in adults. Implementation of models/protocols may be delivered by and/or with the assistance of community health workers and/or community-based organizations to ensure cultural and linguistically appropriate delivery of services
and sustainability. Funded projects will employ a strong theoretical framework to foster replicability, specifying community factors and resources that enable sustainability. Models/protocols will: (1) Describe the roles of family in the intervention, provide
detailed family-based topics to be embedded in interventions, assess the quality and extent of family participation necessary for positive diabetes markers and health outcomes for persons with diabetes and family members; (2) Delineate how the model(s) takes
into account and is (are) tailored to cultural factors/Social Determinants Of Health that may affect the adoption of self-management activities and behaviors associated with diabetes prevention; and (3) Identify lifestyle modifications and community supports
(e.g., sustainable resources/institutions for physical activity and nutrition) that build and reinforce behavioral changes conducive to diabetes control and prevention that may be strengthened through reciprocal influence. BACKGROUND: This initiative is based
on well documented racial and ethnic disparities in diabetes. According to the National Diabetes Statistics Report, 2020 (CDC, 2020) prevalence of diagnosed diabetes is highest among American Indians/Alaska Natives (14.7%), people of Hispanic origin (12.5%),
and non- Hispanic blacks (11.7%), followed by non-Hispanic Asians (9.2%) and non-Hispanic whites (7.5%). Involving family members in diabetes self-care and prevention interventions is thought to positively influence patients' diabetes outcomes. However, it
is unclear how family involvement operates in Type 2 diabetes interventions and what factors can best affect patient and family members' health outcomes in different racial and ethnic communities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date: November 15, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated application deadline: February 15, 2021.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=328523__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzxk0qyNFE$">Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Notice is to alert the community that NIH plans to publish a set of Funding Opportunity Announcements (FOAs) as part of the Helping to End Addiction Long-termSM (HEAL)
Initiative to support research project sites, a Data Coordinating Center, and a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. This Notice is being provided to allow potential applicants sufficient time to form meaningful
collaborations and develop responsive applications. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning
at birth and extending through middle childhood. The study will comprise a normative sample that represents the diversity of pregnant women in the US population, a cohort of women who have used opioids and other substances during pregnancy will also be recruited,
and a comparison group from similar backgrounds/environments as the cohort of women who have used substances. The study is intended to create a well-characterized cohort of children in order to examine the developmental impact of pre/postnatal drug exposure
and multiple other genetic and environmental factors that affect risk or resilience in various health and mental health domains. Anonymized data from this cohort will be made available to the broader research community during the course of the study to maximize
their utility. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date: November 1, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated application deadline: March 1, 2021.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=328518__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxYu0T3BA$">Notice of Intent to Publish a Funding Opportunity Announcement for INIA Research Project (U01 Clinical Trial
Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The National Institute on Alcohol Abuse and Alcoholism intends to renew an initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for collaborative research
projects (U01) to investigate brain mechanisms of excessive alcohol drinking and related phenotypes associated with alcohol use disorder (AUD). The U01s are components of a Consortium on the Integrative Neuroscience Initiative on Alcoholism (INIA).
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date: October 15, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated application deadline: May 18, 2021.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=328447__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzxdnudj3s$">Emerging Issues in Maternal and Child Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To address emerging issues in maternal and child health.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date: January 9, 2021.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated application deadline: April 9, 2021.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=328459__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2Ugzxc-vkp8E$">Maternal and Child Health Leadership, Education, and Advancement in Undergraduate Pathways (LEAP) Training
Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the Maternal and Child Health Pipeline Training Program is to promote the development of a culturally diverse and representative health care workforce by recruiting undergraduate
training students from economically and educationally disadvantaged backgrounds (including racial and ethnic minorities) into maternal and child health professions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date: October 8, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated application deadline: January 6, 2021.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=328414__;!!PhOWcWs!lMgNUNTq4_ZReTe1Fik54G-Sriv2S8Mma1thE80_qPrLkVsjP56oLpUIMZiJ0jpBKkUSaoa2UgzxahkxuTA$">Rapid Response Rural Data Analysis and Issue Specific Rural Research Studies</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this program is to assist rural communities with conducting rapid data analyses and short term issue-specific rural research studies to understand the impact of current
and proposed policies and regulations as well as provide information that will improve access to health care and population health in rural America. Due to the nature of rural policy analysis and formulation, rural organizations and health care providers often
require timely information that is available only through specialized analysis of databases of information compiled by the Centers for Medicare & Medicaid Services (CMS), other federal and state agencies, or private organizations. The awardee is responsible
for collaborating with HHS agencies to compile and analyze the data that is requested in a timely manner. The awardee will also collaborate with rural stakeholders to determine what data sets are needed. These collaborative efforts are vital as most rural
groups and individuals do not have the capacity to store the data sets, the staff expertise to refine and analyze the data nor the technology necessary to run statistical analyses.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date: November 30, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated application deadline: January 29, 2021.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><o:p></o:p></p>
</div>
</body>
</html>